FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891635225> ?p ?o ?g. }

• W2891635225 abstract "We investigated the effect of crenezumab, a humanized anti-amyloid-beta (Aβ) immunoglobulin (Ig)G4 monoclonal antibody, on biomarkers of amyloid pathology, neurodegeneration, and disease progression in patients with mild-to-moderate Alzheimer’s disease (AD). This double-blind, placebo-controlled, randomized phase II study enrolled patients with mild-to-moderate AD and a Mini-Mental State Examination (MMSE) score of 18–26. In part 1 of the study, patients were 2:1 randomized to receive low-dose subcutaneous (SC) 300 mg crenezumab every 2 weeks (q2w) or placebo for 68 weeks; in part 2, patients were 2:1 randomized to receive high-dose intravenous (IV) 15 mg/kg crenezumab every 4 weeks (q4w) or placebo for 68 weeks. The primary endpoint was change in amyloid burden from baseline to week 69 assessed by florbetapir positron emission tomography (PET) in the modified intent-to-treat population. Secondary endpoints were change from baseline to week 69 in cerebrospinal fluid (CSF) biomarkers and fluorodeoxyglucose PET, and change from baseline to week 73 in 12-point Alzheimer’s Disease Assessment Scale cognitive subscale (ADAS-Cog12) and Clinical Dementia Rating Sum of Boxes (CDR-SB). Safety was assessed in patients who received at least one dose of study treatment. From August 2011 to September 2012, 91 patients were enrolled and randomized (low-dose SC cohort: crenezumab (n = 26) or placebo (n = 13); high-dose IV cohort: crenezumab (n = 36) or placebo (n = 16)). The primary endpoint was not met using a prespecified cerebellar reference region to calculate standard uptake value ratios (SUVRs) from florbetapir PET. Exploratory analyses using subcortical white matter reference regions showed nonsignificant trends toward slower accumulation of plaque amyloid in the high-dose IV cohort. In both cohorts, a significant mean increase from baseline in CSF Aβ(1–42) levels versus placebo was observed. Nonsignificant trends toward ADAS-Cog12 and CDR-SB benefits were identified in a mild (MMSE 20–26) subset of the high-dose IV cohort. No amyloid-related imaging abnormalities due to edema/effusion were observed. The primary endpoint was not met. Exploratory findings suggest potential Aβ target engagement with crenezumab and possible slower accumulation of plaque amyloid. Studies investigating the effects of higher doses of crenezumab on amyloid load and disease progression are ongoing. ClinicalTrials.gov, NCT01397578 . Registered on 18 July 2011." @default.
• W2891635225 created "2018-09-27" @default.
• W2891635225 creator A5002183686 @default.
• W2891635225 creator A5004794322 @default.
• W2891635225 creator A5005477431 @default.
• W2891635225 creator A5005868870 @default.
• W2891635225 creator A5010338575 @default.
• W2891635225 creator A5013949966 @default.
• W2891635225 creator A5014512408 @default.
• W2891635225 creator A5020204458 @default.
• W2891635225 creator A5021896055 @default.
• W2891635225 creator A5024864608 @default.
• W2891635225 creator A5027663167 @default.
• W2891635225 creator A5029105145 @default.
• W2891635225 creator A5029527447 @default.
• W2891635225 creator A5034311486 @default.
• W2891635225 creator A5047768726 @default.
• W2891635225 creator A5050777990 @default.
• W2891635225 creator A5076777565 @default.
• W2891635225 creator A5080382188 @default.
• W2891635225 creator A5091201149 @default.
• W2891635225 date "2018-09-19" @default.
• W2891635225 modified "2023-10-14" @default.
• W2891635225 title "Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)" @default.
• W2891635225 cites W1847168837 @default.
• W2891635225 cites W1894015957 @default.
• W2891635225 cites W2004136146 @default.
• W2891635225 cites W2004535959 @default.
• W2891635225 cites W2006096283 @default.
• W2891635225 cites W2008854521 @default.
• W2891635225 cites W2020745232 @default.
• W2891635225 cites W2028942474 @default.
• W2891635225 cites W2029506047 @default.
• W2891635225 cites W2036288989 @default.
• W2891635225 cites W2043827506 @default.
• W2891635225 cites W2048810707 @default.
• W2891635225 cites W2058161128 @default.
• W2891635225 cites W2062527635 @default.
• W2891635225 cites W2063808031 @default.
• W2891635225 cites W2079749054 @default.
• W2891635225 cites W2080531304 @default.
• W2891635225 cites W2082429191 @default.
• W2891635225 cites W2096410114 @default.
• W2891635225 cites W2111951761 @default.
• W2891635225 cites W2118753807 @default.
• W2891635225 cites W2125537950 @default.
• W2891635225 cites W2132842417 @default.
• W2891635225 cites W2148080316 @default.
• W2891635225 cites W2150231759 @default.
• W2891635225 cites W2166976202 @default.
• W2891635225 cites W2167311298 @default.
• W2891635225 cites W2257069458 @default.
• W2891635225 cites W2257300023 @default.
• W2891635225 cites W2510806376 @default.
• W2891635225 cites W2601400544 @default.
• W2891635225 cites W2772872651 @default.
• W2891635225 cites W2787469674 @default.
• W2891635225 cites W2787612390 @default.
• W2891635225 cites W2800202520 @default.
• W2891635225 cites W2805469564 @default.
• W2891635225 cites W2896489473 @default.
• W2891635225 cites W2898329077 @default.
• W2891635225 cites W950120787 @default.
• W2891635225 doi "https://doi.org/10.1186/s13195-018-0424-5" @default.
• W2891635225 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6146627" @default.
• W2891635225 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30231896" @default.
• W2891635225 hasPublicationYear "2018" @default.
• W2891635225 type Work @default.
• W2891635225 sameAs 2891635225 @default.
• W2891635225 citedByCount "95" @default.
• W2891635225 countsByYear W28916352252019 @default.
• W2891635225 countsByYear W28916352252020 @default.
• W2891635225 countsByYear W28916352252021 @default.
• W2891635225 countsByYear W28916352252022 @default.
• W2891635225 countsByYear W28916352252023 @default.
• W2891635225 crossrefType "journal-article" @default.
• W2891635225 hasAuthorship W2891635225A5002183686 @default.
• W2891635225 hasAuthorship W2891635225A5004794322 @default.
• W2891635225 hasAuthorship W2891635225A5005477431 @default.
• W2891635225 hasAuthorship W2891635225A5005868870 @default.
• W2891635225 hasAuthorship W2891635225A5010338575 @default.
• W2891635225 hasAuthorship W2891635225A5013949966 @default.
• W2891635225 hasAuthorship W2891635225A5014512408 @default.
• W2891635225 hasAuthorship W2891635225A5020204458 @default.
• W2891635225 hasAuthorship W2891635225A5021896055 @default.
• W2891635225 hasAuthorship W2891635225A5024864608 @default.
• W2891635225 hasAuthorship W2891635225A5027663167 @default.
• W2891635225 hasAuthorship W2891635225A5029105145 @default.
• W2891635225 hasAuthorship W2891635225A5029527447 @default.
• W2891635225 hasAuthorship W2891635225A5034311486 @default.
• W2891635225 hasAuthorship W2891635225A5047768726 @default.
• W2891635225 hasAuthorship W2891635225A5050777990 @default.
• W2891635225 hasAuthorship W2891635225A5076777565 @default.
• W2891635225 hasAuthorship W2891635225A5080382188 @default.
• W2891635225 hasAuthorship W2891635225A5091201149 @default.
• W2891635225 hasBestOaLocation W28916352251 @default.
• W2891635225 hasConcept C126322002 @default.
• W2891635225 hasConcept C141341695 @default.
• W2891635225 hasConcept C142724271 @default.
• W2891635225 hasConcept C168563851 @default.

• next